{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:33:05Z","timestamp":1761708785301},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/cco.0b013e32835689a3","type":"journal-article","created":{"date-parts":[[2012,8,7]],"date-time":"2012-08-07T07:45:59Z","timestamp":1344325559000},"page":"466-474","source":"Crossref","is-referenced-by-count":11,"title":["Current treatment strategies in Hodgkin lymphomas"],"prefix":"10.1097","volume":"24","author":[{"given":"Amanda","family":"Copeland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkins Lymphoma When High-Dose Salvage Is Planned.","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-Intensification in Early Unfavorable Hodgkins Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial.","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkins lymphoma.","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkins lymphoma.","volume":"9","author":"Kuppers","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood.V99.2.618","article-title":"Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2012-01-402792","article-title":"A phase II study of rituximab-ABVD in classical Hodgkin lymphoma.","volume":"119","author":"Kasamon","year":"2012","journal-title":"Blood"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab Vedotin (SGN-35).","volume":"17","author":"Katz","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd3629","article-title":"Brentuximab vedotin.","volume":"11","author":"Younes","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/cncr.22911","article-title":"The impact of pre and posttransplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation.","volume":"110","author":"Filmont","year":"2007","journal-title":"Cancer"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2005-11-006957","article-title":"Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.","volume":"109","author":"Schot","year":"2007","journal-title":"Blood"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2141.2011.08618.x","article-title":"Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsedrefractory Hodgkin lymphoma.","volume":"154","author":"Fanale","year":"2011","journal-title":"Br J Haematol"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/299065a0","article-title":"Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkins disease and a subset of normal lymphoid cells.","volume":"299","author":"Schwab","year":"1982","journal-title":"Nature"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/CCO.0b013e32834bb8a7","article-title":"CD30-targeted antibody therapy.","volume":"23","author":"Younes","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/1078-0432.CCR-11-1425","article-title":"A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with RelapsedRefractory CD30-Positive Hematologic Malignancies.","volume":"18","author":"Fanale","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkins Lymphoma.","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkins lymphoma: CALGB 59804.","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2005.00546.x","article-title":"Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.","volume":"76","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.4161\/cc.5.15.3099","article-title":"Activation of Mitochondrial Pathway is Crucial for Tumor Selective Induction of Apoptosis by LAQ824.","volume":"5","author":"Wang","year":"2006","journal-title":"Cell Cycle"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-04-019711","article-title":"Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.","volume":"109","author":"Brogdon","year":"2007","journal-title":"Blood"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical Studies of Histone Deacetylase Inhibitors.","volume":"15","author":"Prince","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.2010.08342.x","article-title":"The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.","volume":"151","author":"Buglio","year":"2010","journal-title":"Br J Haematol"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2008-01-133769","article-title":"Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.","volume":"112","author":"Buglio","year":"2008","journal-title":"Blood"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkins lymphoma: an open-label, single-arm, phase 2 trial.","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in Patients With RelapsedRefractory Hodgkins Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study.","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/blood-2006-12-064360","article-title":"RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4 T cells in Hodgkin lymphoma.","volume":"110","author":"Chemnitz","year":"2007","journal-title":"Blood"},{"key":"R33-3-20210128","doi-asserted-by":"crossref","first-page":"13138","DOI":"10.1073\/pnas.0603107103","article-title":"OX40 ligand shuts down IL-10-producing regulatory T cells.","volume":"103","author":"Ito","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R34-3-20210128","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4049\/jimmunol.179.3.1427","article-title":"Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25Foxp3 T cells.","volume":"179","author":"So","year":"2007","journal-title":"J Immunol"},{"key":"R35-3-20210128","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood-2007-01-070748","article-title":"OX40 costimulation turns off Foxp3 Tregs.","volume":"110","author":"Vu","year":"2007","journal-title":"Blood"},{"key":"R36-3-20210128","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2010-08-303701","article-title":"HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.","volume":"117","author":"Buglio","year":"2011","journal-title":"Blood"},{"key":"R37-3-20210128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/978-0-387-89520-8_6","article-title":"OX40 (CD134) and OX40L.","volume":"647","author":"Gough","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"R38-3-20210128","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nri1371","article-title":"Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.","volume":"4","author":"Sugamura","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"R39-3-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1615\/CritRevImmunol.v29.i3.10","article-title":"The role of OX40-mediated co-stimulation in T-cell activation and survival.","volume":"29","author":"Redmond","year":"2009","journal-title":"Crit Rev Immunol"},{"key":"R40-3-20210128","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1172\/JCI32693","article-title":"OX40 ligand expressed by DCs costimulates NKT and CD4 Th cell antitumor immunity in mice.","volume":"117","author":"Zaini","year":"2007","journal-title":"J Clin Invest"},{"key":"R41-3-20210128","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent.","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"R42-3-20210128","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/10428194.2011.608448","article-title":"A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.","volume":"53","author":"Kirschbaum","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R43-3-20210128","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1021\/jm800251w","article-title":"Discovery of N-(2-Aminophenyl)-4-(4-pyridin-3-ylpyrimidin-2-ylamino)methylbenzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor.","volume":"51","author":"Zhou","year":"2008","journal-title":"J Med Chem"},{"key":"R44-3-20210128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","article-title":"MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.","volume":"7","author":"Fournel","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"R46-3-20210128","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2011-01-331421","article-title":"The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.","volume":"119","author":"Lemoine","year":"2012","journal-title":"Blood"},{"key":"R48-3-20210128","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.exphem.2011.07.002","article-title":"The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.","volume":"39","author":"Jona","year":"2011","journal-title":"Exp Hematol"},{"key":"R50-3-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-08-0801","article-title":"Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.","volume":"8","author":"Ihle","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"R51-3-20210128","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/onc.2008.313","article-title":"PI3KAkt: getting it right matters.","volume":"27","author":"Franke","year":"2008","journal-title":"Oncogene"},{"key":"R53-3-20210128","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.2005.05881.x","article-title":"Inhibition of the phosphatidylinositol-3kinaseAkt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.","volume":"132","author":"Georgakis","year":"2006","journal-title":"Br J Haematol"},{"key":"R54-3-20210128","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2004-11-4513","article-title":"A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein I2 and NF-IB activity in Hodgkin and anaplastic large cell lymphomas.","volume":"106","author":"Jundt","year":"2005","journal-title":"Blood"},{"key":"R55-3-20210128","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.4049\/jimmunol.178.4.2163","article-title":"A Role for Mammalian Target of Rapamycin in Regulating T Cell Activation versus Anergy.","volume":"178","author":"Zheng","year":"2007","journal-title":"J Immunol"},{"key":"R56-3-20210128","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","article-title":"Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus.","volume":"66","author":"Del Bufalo","year":"2006","journal-title":"Cancer Res"},{"key":"R59-3-20210128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.2711","article-title":"The classical Hodgkins lymphoma microenvironment and its role in promoting tumour growth and immune escape.","volume":"221","author":"Aldinucci","year":"2011","journal-title":"J Pathol"},{"key":"R60-3-20210128","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/ijc.21539","article-title":"Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells.","volume":"118","author":"Baus","year":"2006","journal-title":"Int J Cancer"},{"key":"R61-3-20210128","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/sj.leu.2403750","article-title":"STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis.","volume":"19","author":"Holtick","year":"2005","journal-title":"Leukemia"},{"key":"R62-3-20210128","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma.","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"R63-3-20210128","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccr.2010.11.013","article-title":"Cooperative Epigenetic Modulation by Cancer Amplicon Genes.","volume":"18","author":"Rui","year":"2010","journal-title":"Cancer Cell"},{"key":"R64-3-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bcj.2011.46","article-title":"The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.","volume":"1","author":"Derenzini","year":"2011","journal-title":"Blood Cancer J"},{"key":"R65-3-20210128","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"R66-3-20210128","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPMALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R67-3-20210128","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1349-7006.2009.01302.x","article-title":"B7-H1 expression is regulated by MEKERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.","volume":"100","author":"Yamamoto","year":"2009","journal-title":"Cancer Sci"},{"key":"R68-3-20210128","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"R69-3-20210128","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"key":"R71-3-20210128","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies.","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"R72-3-20210128","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"R73-3-20210128","first-page":"3052","article-title":"Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma.","volume":"112","author":"Kuruvilla","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e32835689a3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T06:37:02Z","timestamp":1714286222000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201209000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32835689a3","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}